Oncolytics Biotech (ONCY) Cash from Operations (2009 - 2025)

Oncolytics Biotech (ONCY) has reported Cash from Operations for 17 consecutive years, with -$4.8 million the latest figure, recorded in Q3 2025.

• On a quarterly basis, Cash from Operations fell 36.44% year-over-year to -$4.8 million in Q3 2025; TTM through Sep 2025 was -$18.9 million, a 1.93% decrease from a year earlier, with the FY2025 full-year figure at -$20.1 million, down 1.15% from the prior year.
• Cash from Operations was -$4.8 million for Q3 2025 at Oncolytics Biotech, down from -$3.9 million in the prior quarter.
• Over five years, Cash from Operations peaked at -$3.0 million in Q3 2021 and troughed at -$6.3 million in Q2 2023.
• A 5-year average of -$4.7 million and a median of -$4.8 million in 2025 frame the typical range for Cash from Operations.
• The widest YoY moves for Cash from Operations: up 35.46% in 2021, down 49.13% in 2021.
• Over 5 years, Cash from Operations stood at -$5.0 million in 2021, then climbed by 12.94% to -$4.4 million in 2022, then declined by 2.81% to -$4.5 million in 2023, then slipped by 24.86% to -$5.6 million in 2024, then advanced by 13.95% to -$4.8 million in 2025.
• The last three Cash from Operations figures came in at -$4.8 million (Q3 2025), -$3.9 million (Q2 2025), and -$4.5 million (Q1 2025), per Business Quant data.